‘EXTREME VOLATILITY’: Expert advises how to safely invest in cannabis, psychedelics

Key Concepts

• Cannabis Rescheduling: The reclassification of state-licensed medical marijuana by the Trump administration to facilitate easier commerce.
• Psychedelic Biotech: The use of psychedelic substances in clinical settings for treating conditions like PTSD, traumatic brain injury, and treatment-resistant depression.
• OTC (Over-the-Counter) Trading: Stocks that trade outside of major exchanges (like NYSE or NASDAQ) due to regulatory constraints, common for U.S. cannabis companies.
• FDA Fast-Track: An executive order aimed at accelerating the review process for psychedelic-based medical treatments.
• Active Management: An investment strategy where fund managers make specific trades to capitalize on market volatility rather than tracking a passive index.

Market Context and Regulatory Shifts

The video discusses a volatile trading session where the Dow Jones Industrial Average recovered from a 600-point deficit to close down only 200 points. A significant driver of market sentiment is the Trump administration's move to reclassify marijuana. While initial reports suggested a broad reclassification, the actual policy focuses on rescheduling state-licensed medical marijuana. This shift is expected to reduce barriers to buying and selling cannabis, providing a major tailwind for U.S.-based cannabis firms.

Cannabis Sector Analysis

Dan Aarons, Managing Director at Advisor Shares, emphasizes a critical distinction between Canadian-listed cannabis stocks and U.S.-based operators.

• Key Holdings:
  • Curaleaf: Highlighted for having the largest footprint in the U.S. and significant operations in Europe.
  • Trulieve: Identified as the leading medical cannabis provider in Florida and several other states.
• Market Dynamics: Because of federal regulatory hurdles, many U.S. cannabis companies currently trade OTC. Aarons argues that the recent executive order and the Attorney General’s sign-off on rescheduling represent the most significant positive development in the history of the U.S. cannabis market.

Psychedelics: Biotech and Volatility

The psychedelics sector is described as a high-growth, high-volatility area of the market. Unlike the cannabis sector, which is viewed as more "mature," the psychedelics market is driven by biotech companies listed on major exchanges (NASDAQ, NYSE, TSX).

• Clinical Applications: These companies are developing treatments for conditions that current pharmaceutical courses fail to address, specifically:
  • Post-Traumatic Stress Disorder (PTSD), particularly among veterans.
  • Traumatic Brain Injury.
  • Treatment-resistant depression.
• Regulatory Support: The White House has issued an executive order to examine and fast-track FDA reviews for these psychedelic treatments.

Investment Strategy and Risk Management

Aarons addresses the extreme volatility inherent in the psychedelics space, noting that these are often micro-cap or small-cap stocks.

• Valuation Drivers: Stock performance is heavily tied to Intellectual Property (IP) and the status of companies within the FDA approval pipeline.
• The Case for ETFs: Aarons advocates for an actively managed fund approach rather than individual stock picking. By holding a diversified basket of 25–30 stocks, the fund mitigates the risk of individual company failure.
• Active Management Advantage: Because the fund is actively managed rather than indexed, managers can trade into the "double-digit" daily volatility to capture opportunities, rather than being forced to hold through extreme swings.

Synthesis

The market is currently reacting to a dual-track regulatory shift: the rescheduling of medical marijuana and the fast-tracking of psychedelic-based medical research. While these sectors offer significant growth potential, they carry distinct risks—regulatory constraints for cannabis and high volatility/clinical trial dependency for psychedelics. The consensus presented is that institutional-grade, actively managed funds are the most effective vehicle for investors to gain exposure to these emerging industries while managing the inherent risks of the underlying assets.